Latanoprost Opko

Quick links

Choose a section

Quick links to important sections

Advertisements

Latanoprost Opko

Advertisements
Advertisements

Treatment option: Hypertension, Glaucoma

Advertisements

Overview of Latanoprost Opko

What is Latanoprost Opko?

Latanoprost Opko is a pharmaceutical solution used in ophthalmology. It contains the active substance latanoprost, which belongs to a group of medications known as prostaglandin analogues. The medication is formulated as an eye drop solution intended for topical application to the eye.

Mechanism of Action

The primary function of Latanoprost Opko is to manage the internal pressure of the eye. The eye constantly produces a fluid known as aqueous humor, which must drain at a consistent rate to maintain healthy intraocular pressure. Latanoprost works by increasing the natural outflow of this fluid from the eye into the bloodstream. By facilitating this drainage, the medication helps to lower elevated intraocular pressure.

Clinical Applications

This medication is primarily utilized in the management of specific ocular conditions characterized by increased pressure within the eye:

  • Open-Angle Glaucoma: A chronic condition where the eye's drainage system becomes less efficient over time, leading to gradual pressure buildup.
  • Ocular Hypertension: A state where the pressure inside the eye is higher than the normal range, even if no immediate damage to the optic nerve is detected.

Lowering intraocular pressure is a standard approach to help prevent or slow the progression of vision loss associated with these conditions.

Regulatory References

  1. Latanoprost - StatPearls
Advertisements

What side effects are possible with Latanoprost Opko?

Possible side effects and safety information

Officially Documented Adverse Reactions

The safety profile of Latanoprost is primarily defined by effects on the Eye Disorders system/organ class, though adverse reactions in non-ocular systems are also officially documented. The most frequently occurring adverse reaction is Iris hyperpigmentation, classified as Very Common (occurring in ge1/10 individuals) in official regulatory documents. This is a gradual increase in brown pigment within the iris that is documented as likely to be permanent upon discontinuation of the medicine.

Other Very Common events include mild to moderate conjunctival hyperaemia (eye redness).

Reactions classified as Common (ge1/100 to <1/10) include local symptoms such as punctate keratitis, burning or stinging upon instillation, eye pain, dry eye, and changes to the eyelashes (increased length, thickness, pigmentation). Eyelash changes are generally noted as reversible upon discontinuation.

General and Serious Safety Considerations

Adverse reactions classified as Uncommon or Rare include events such as keratitis, eyelid oedema, dizziness, headache, and skin rash. Serious adverse reactions listed in official labeling include macular oedema (including cystoid macular oedema) and intraocular inflammation (iritis/uveitis). Non-ocular serious events documented in post-marketing reports include exacerbation of asthma and angina pectoris.

Population and Administration Safety Notes

Latanoprost is officially contraindicated in individuals with known hypersensitivity to the active substance or any excipients. Use during pregnancy is not recommended, and lactation should be stopped if treatment is considered necessary. Regulatory documentation includes a note that the co-administration of two or more prostaglandin analogues is not recommended due to the potential for a paradoxical increase in intraocular pressure.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile for Latanoprost Opko based on effects observed during studies involving systemic overexposure, such as high-dose intravenous infusion, which results in plasma concentrations significantly greater than those achieved with standard ocular application.

Documented Manifestations

In cases of systemic overdosage, regulatory sources document manifestations that may include abdominal pain, dizziness, fatigue, hot flushes, nausea, and sweating. These effects are associated with the drug's properties at excessively high exposure levels. The official labeling confirms that no life-threatening outcomes are explicitly documented in the overdosage sections.


Official Emergency Response

In the event of accidental ingestion or suspected systemic overexposure, urgent medical attention is required for management. The regulatory framework mandates that treatment for an overdosage event must be symptomatic and supportive. It is officially stated that no specific antidote is known for latanoprost overdosage. Patients presenting with the documented systemic symptoms must seek professional medical care immediately. This approach reflects the universally mandated action across governmental regulatory sources.

Advertisements

Therapeutic Uses of Latanoprost Opko

Management of Primary Glaucoma and Ocular Hypertension

Latanoprost Opko is primarily used in situations involving symptoms related to heightened physiological activity, specifically the abnormally high pressure inside the eye (IOP), which defines conditions like Primary Open-Angle Glaucoma and Ocular Hypertension. This medication is used to help with pressure inside the eye in adults and may be part of symptomatic management for childhood glaucoma. This therapeutic domain addresses the symptoms linked to organ-specific functional stress, which, if left unmanaged, may assist with maintaining functional stability and general comfort in the long run.

The medicine plays a role in managing the risk associated with progressive loss of visual function, a benefit that contributes to easing the overall symptom load and may help reduce functional strain over time. This approach helps maintain a sense of stability during symptomatic phases. Clinically, it is relevant for easing the impact of the core indications, which include Primary Open-Angle Glaucoma, Ocular Hypertension, and certain types of secondary glaucoma.

“This medication is commonly used when supportive symptom management is appropriate for conditions marked by increased physiological stress within the eye.”

Summary of Therapeutic Focus

Property Description
Therapeutic Area Management of Primary Open-Angle Glaucoma
Marker Managed Elevated Intraocular Pressure (IOP)
Therapeutic Role Monotherapy or combination therapy
Benefit Focus Applied for managing visual function

Regulatory References

  1. European Medicines Agency (EMA) overview
Advertisements

Eligibility and Restrictions for Use

This section details the official population eligibility and non-eligibility for Latanoprost Opko, strictly based on government regulatory documentation.

Eligibility Scope

Classification Status and Population Regulatory Basis
Contraindicated Patients with known hypersensitivity to the active substance, Latanoprost, or any excipients, including Benzalkonium Chloride (preservative). Absolute prohibition.
Use Allowed Adults and pediatric patients (children and adolescents) for the reduction of elevated Intraocular Pressure (IOP). Established use.
Not Recommended Individuals who are pregnant or breastfeeding. Safety in human pregnancy is not established, and the drug may pass into breast milk. Conditional exclusion.

Eligibility-Related Restrictions

Official labeling requires caution or avoidance in specific clinical situations:

  • Active Keratitis: The medicine should be avoided in cases of active Herpes Simplex Keratitis because inflammation may be exacerbated.
  • Ocular Inflammation Risk: Use with caution is required for patients with a history of intraocular inflammation (e.g., iritis or uveitis) or those at risk of macular edema (e.g., aphakic or pseudophakic patients with a torn lens capsule).
  • Age Limits: Data on efficacy and safety are very limited for infants under 1 year of age, and no data are available for preterm infants.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Latanoprost outlines a specific interaction profile focused on administration compatibility and pharmacodynamic effects within the ocular environment, rather than systemic metabolic interactions.

Pharmacodynamic Interaction Restrictions

Co-administration with two or more prostaglandins, prostaglandin analogues, or prostaglandin derivatives is not recommended. This restriction is based on regulatory documentation showing that the combined use of multiple prostaglandin agents can lead to a paradoxical elevation in Intraocular Pressure (IOP), which directly compromises the primary therapeutic objective of pressure reduction. This classification defines a core limitation of use within its own pharmacological class.

Administration Timing and Physical Compatibility

Administration requires mandatory time separation from other topical products. All other topical ophthalmic drug products must be administered at least five (5) minutes apart from Latanoprost Opko. This timing rule ensures proper drug absorption and prevents physical interference. Furthermore, official documentation notes that in vitro precipitation occurs when Latanoprost is mixed with eye drops containing thimerosal, making the separation of administration critical for this specific combination.

Interaction Type Requirement/Restriction
Prostaglandin Analogues Co-administration is not recommended
Other Eye Drops Must be separated by at least five minutes
Thimerosal-Containing Drops Separation mandatory due to precipitation risk
Advertisements

Mechanism of Action

Latanoprost is an ester prodrug that undergoes hydrolysis by corneal esterases to yield its biologically active metabolite, latanoprost acid. This active acid functions as a prostanoid selective FP receptor agonist, targeting the prostaglandin F2alpha receptor which is a G-protein-coupled receptor expressed in the ciliary muscle and other ocular tissues.

Binding of latanoprost acid to the FP receptor initiates an intracellular signaling cascade, ultimately leading to remodeling of the extracellular matrix within the ciliary muscle and sclera. This process involves the upregulation of matrix metalloproteinases (MMPs), which facilitate the degradation and reorganization of collagen and other matrix components. The consequent structural change increases the porosity and permeability of the tissue spaces surrounding the ciliary muscle bundles.

At the system level, this molecular and cellular remodeling results in a reduction in resistance to fluid flow through the uveoscleral pathway, thereby increasing the total aqueous humor outflow rate. This modulation of outflow dynamics serves as the primary mechanism by which the drug exerts its physiological effect.

Advertisements

Dosage and Administration Information

How to use Latanoprost Opko: Administration Guidelines

This section outlines the procedure for the administration of Latanoprost eye drops.


Administration Scope

Feature Instruction
Route of Administration Ophthalmic (Instill in the eye)
Dosing Schedule One drop in the affected eye(s) once daily. The dosage should not exceed once daily, as more frequent administration may reduce the intraocular pressure (IOP) lowering effect.
Timing & Frequency Administer in the evening for optimal effect. Administer daily.
Missed Dose Rule If a dose is missed, skip the missed dose and continue with the next scheduled dose as normal. Do not double up to compensate for a missed dose.
Age-Group Rules Recommended for adults and the elderly. Safety and effectiveness in the pediatric population have not been established.

Procedural Steps and Special Conditions

Required Preparation: Remove contact lenses before instillation. Lenses may be reinserted 15 minutes after administration.

Instillation Sequence:

  1. Wash hands thoroughly.
  2. Tilt the head back and pull down the lower eyelid to create a small pouch.
  3. Holding the dropper, place one drop into the eye, taking care to avoid touching the tip to the eye, eyelid, or any other surface.
  4. After instillation, gently close the eye.
  5. Immediately apply gentle pressure to the inner corner of the eye (lachrymal sac) for one minute. This procedure, known as punctal occlusion, helps reduce systemic absorption of the medication.
  6. If using other topical ophthalmic drugs, administer them at least five minutes apart.
Advertisements

Recent Clinical Evidence

Latanoprost Opko: Recent Clinical Evidence

Clinical research on latanoprost, a prostaglandin F2alpha analogue, primarily focuses on its use for reducing intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). The goal of this treatment is to preserve the visual field by controlling this key risk factor for vision loss.

Efficacy in Intraocular Pressure Reduction

Multiple randomized controlled trials (RCTs) have investigated the effect of latanoprost on IOP. These studies consistently demonstrate that the treatment is associated with a significant reduction in IOP from baseline values.

  • Magnitude of IOP Reduction: Studies have generally noted that latanoprost 0.005% ophthalmic solution is associated with a reduction in IOP that is sustained over 24 hours, allowing for once-daily use. Average IOP reduction observed in clinical settings is typically in the range of 30% to 35% from pretreatment levels.
  • Visual Field Preservation: The United Kingdom Glaucoma Treatment Study (UKGTS), a major placebo-controlled RCT, explored outcomes beyond IOP. Findings from this study suggested that treatment with latanoprost was associated with longer visual field (VF) survival compared to placebo, indicating a reduced rate of VF deterioration over the study period.

Comparative and Formulation Research

Research has also focused on comparing latanoprost to other common glaucoma treatments and newer formulations.

Comparison Primary Finding from Studies
vs. Timolol Studies found that once-daily latanoprost 0.005% was comparable to, or numerically reduced IOP more effectively than, twice-daily timolol 0.5% in patients with OAG or OHT.
Preservative-Free Formulations Newer preservative-free latanoprost formulations have been studied. These trials suggested that the preservative-free option had IOP-lowering effects similar to preserved versions, but with potentially improved tolerability, showing lower incidences of ocular adverse events like irritation and conjunctival hyperemia.

Key Studies & References

  1. Relative Efficacy and Safety of Latanoprost versus Timolol in Patients with Open-Angle Glaucoma: A Systematic Review and Meta-Analysis
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Latanoprost Opko (FAQ)

Q: Does it make you sleepy?

Official information indicates that this medicine has been associated with central nervous system effects. This includes somnolence, which is the medical term for unusual sleepiness or drowsiness, observed in clinical trials. Patients experiencing sleepiness may wish to discuss their activities with a healthcare provider.

Q: What are the storage requirements for this medicine?

According to the official product information, the tablets should be stored at controlled room temperature. This usually means maintaining a temperature between 20 C and 25 C (68 F and 77 F). Final instructions are always found on the product's labeling, which provides the most precise guidance.

Q: What if I forget to take my dose?

Regulatory guidance addresses what to do if a dose is missed. It suggests that the missed dose be taken as soon as possible unless it is nearly time for the next scheduled dose. Official documents consistently state not to double a dose to make up for a missed one.

Q: Can I drink alcohol while taking this medicine?

Official warnings and precautions sections note that concomitant use with alcohol is not recommended. This is because combining the medicine with alcohol may increase the risk of certain adverse effects, particularly those affecting the central nervous system.

Advertisements

How should Latanoprost Opko be stored and disposed of?

Storage and Disposal of Latanoprost Ophthalmic Solution

Official regulatory documents define strict conditions for storing and disposing of latanoprost solution, emphasizing temperature control and stability limits.

Storage Requirements

Condition Requirement Constraint
Unopened Refrigerated: 2 C to 8 C (36 F to 46 F) Must not freeze
Opened Room Temperature: Up to 25 C (77 F) Discard 6 weeks after opening

Unopened bottles must be kept in the original outer carton to protect from light. The medication must be stored out of the sight and reach of children. Once opened, the bottle should be kept tightly closed when not in use.

Disposal

Unused or expired latanoprost solution must be disposed of according to local regulations. The product should not be thrown into household trash or wastewater without following established household disposal procedures for medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Latanoprost Opko found in:

A-Z Index: